Mogrify, a regenerative medicine company, has appointed Dr Jonathan Appleby as its Chief Scientific Officer.
Dr Appleby has decades of industry experience in developing conventional and advanced therapeutics, and will focus on leading the advancement of Mogrify’s theapeutic programmes into clinical development.
This will include projects in otology, ophthalmology and diabetes.
Jonathan has operated in all phases of therapeutic development — from discovery to commercial launch — and will join Mogrify from Cell and Gene Therapy Catapult, where he was the Chief Scientific Officer and Executive Director.
Prior to his time at CGTC, Dr Appleby was the Chief Scientific Officer for GSK’s Rare Diseases Unit, where he led the team that developed Strimvelis, a CD34+ autologous stem cell gene therapy.
He had the same role at ARSA gene therapy, which was later out-licensed to Orchard Therapeutics.
CEO of Mogrify, Dr Darrin Disley, said: “We are thrilled to welcome Jon to the Mogrify Executive Team. Following a comprehensive global search that considered experienced medicine makers from across the cell and gene therapy paradigm, Jon’s particular expertise in advancing innovative and first-in-class medicines for patients with limited treatment options makes him the ideal candidate for leading Mogrify’s pipeline of novel in vivo reprogramming therapies through pre-clinical translation and into first in-human studies.”